Evoke Pharma (EVOK) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Noble Financial Keeps Evoke Pharma (EVOK) at 'Hold' Following Q2 Numbers; Still Awaiting Development Plans
August 16, 2016 8:43 AM EDTNoble Financial affirms Evoke Pharma (Nasdaq: EVOK) with a Hold rating following Q2 results issued Monday night.
Analyst Nathan Cali noted the following on Tuesday:
Operational costs incrementally lower. August 15th, 2016, reported second quarter financial results; no revenues as expected; SG&A $802,655... MoreFBR Capital Reiterates Outperform on Evoke Pharma (EVOK) Following 2Q Report
August 16, 2016 8:42 AM EDTFBR Capital reiterated an Outperform rating and $9.00 price target on Evoke Pharma (NASDAQ: EVOK) following the company's 2Q earnings report. EVOK reported a 2Q16 net loss of $3.0 million, or ($0.41)/ share, versus estimates of a net loss of $3.4 million, or ($0.47)/share.
Analyst Vernon Bernardino commented, "On... More
